Inzoomen: druk op uw toetsenbord op CtrlCommand + +
Uitzoomen: druk op uw toetsenbord op CtrlCommand + -
Gebruik knijpzoomen om eenvoudig in en uit te zoomen

TRANSDERMIS study

Laatste wijziging: 24 januari 2022

Low-level laser therapy as a tool for the prevention and management of radiodermatitis in breast cancer patients

 

Principal Investigator: Prof. Dr. Jeroen Mebis, Researcher: Jolien Robijns

 

90% of the cancer patients undergoing radiotherapy are affected by radiodermatitis or  a painful inflammation of the skin as a result of radiation treatments. Current methods of treatment for radiodermatitis consist of several creams, gels and woundbandages. However, these methods are not sufficiently effective. Therefore, it is important to seek out new techniques for the treatment of radiodermatitis. A recent study by our research group shows that low-level laser therapy (LLLT) is an effective treatment for radiodermatitis in breast cancer patients.

 

In the current study, the use of laser therapy for the prevention and treatment of radiodermatitis in breast cancer patients will be further investigated. Moreover, it will be investigated whether LLLT can regulate the production of inflammatory molecules in the skin to investigate the underlying mechanism of LLLT. Finally, we will also determine the composition of these inflammatory molecules in the skin of patients to explain the variation in the severity of skin reactions. In this way, patients can be classified into risk groups (high or low risk of radiodermatitis) and can receive a better personalized treatment. To investigate this, we will collect skin samples from breast cancer patients undergoing radiotherapy by using a specially designed tape. These tape samples will be analyzed retrospectively for inflammatory molecules.

 

The results of this study will contribute in a better radiation treatment, which also implies an improvement in the quality of life of the patients.